Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Circulation ; 104(16): 1946-51, 2001 Oct 16.
Article in English | MEDLINE | ID: mdl-11602499

ABSTRACT

BACKGROUND: Knowledge of the pathway common to both wave fronts in figure-8 reentrant circuits (ie, the isthmus) is of importance for catheter ablation to stop reentrant ventricular tachycardia. It was hypothesized that quantitative measures of reentry isthmus geometry were interrelated and could be correlated with tachycardia cycle length. METHODS AND RESULTS: A canine infarct model of reentrant ventricular tachycardia in the epicardial border zone with a figure-8 pattern of conduction was used for initial analysis (experiments in 20 canine hearts with monomorphic reentry). Sinus-rhythm and reentry activation maps were constructed, and quantitative (skeletonized) geometric parameters of the isthmus and border zone were measured from the maps. Regression equations were used to determine significant correlation relationships between skeletonized variables, which can be described as follows. Tachycardia cycle length, measured from the ECG R-R interval, increases with increasing isthmus length, width, narrowest width, angle with respect to muscle fibers, and circuit path length determined by use of sinus-rhythm measurements. After this procedure, in 5 test-set experiments, tachycardia cycle length measured from the R-R interval, in combination with regression coefficients calculated from initial experiments, correctly predicted isthmus geometry (mean estimated/actual isthmus overlap 70.5%). Also, the circuit path length determined with sinus-rhythm measurements correctly estimated the tachycardia cycle length (mean error 6.2+/-2.5 ms). CONCLUSIONS: Correlation relationships derived from measurements using reentry and sinus-rhythm activation maps are useful to assess isthmus geometry on the basis of tachycardia cycle length. Such estimates may improve catheter ablation site targeting during clinical electrophysiological study.


Subject(s)
Electrophysiologic Techniques, Cardiac , Heart Conduction System/physiopathology , Heart Rate , Myocardial Infarction/physiopathology , Tachycardia, Ventricular/physiopathology , Animals , Body Surface Potential Mapping , Catheter Ablation/methods , Disease Models, Animal , Dogs , Membrane Potentials , Myocardial Infarction/complications , Tachycardia, Ventricular/complications
2.
Circulation ; 103(8): 1148-56, 2001 Feb 27.
Article in English | MEDLINE | ID: mdl-11222480

ABSTRACT

BACKGROUND: Resetting has been used to characterize reentrant circuits causing clinical tachycardias. METHODS AND RESULTS: To determine the mechanisms of resetting, sustained ventricular tachycardia was induced in dogs with 4-day-old myocardial infarctions by programmed stimulation. Premature stimulation was accomplished from multiple regions within reentrant circuits; resetting curves were constructed and compared with activation maps. Monotonically increasing responses, or a "mixed" response (increasing portion preceded by a flat portion), occurred. All reentrant circuits had a fully excitable gap. Interval-dependent conduction delay and concealed retrograde penetration led to increased resetting response curves. CONCLUSIONS: Multiple mechanisms revealed by mapping cause resetting of reentrant circuits.


Subject(s)
Tachycardia, Ventricular/physiopathology , Animals , Disease Models, Animal , Dogs , Electrophysiology , Heart Conduction System
3.
Circulation ; 99(14): 1843-50, 1999 Apr 13.
Article in English | MEDLINE | ID: mdl-10199881

ABSTRACT

BACKGROUND: Cardiologists often use clinical variables to determine the need for electrophysiological studies to stratify patients for risk of sudden death. It is not clear whether this is rational in patients with coronary artery disease, left ventricular dysfunction, and nonsustained ventricular tachycardia. METHODS AND RESULTS: We analyzed the first 1721 patients enrolled in the Multicenter UnSustained Tachycardia Trial to determine whether clinical variables could predict which patients would have inducible sustained monomorphic ventricular tachycardia. The rate of inducibility of sustained ventricular tachycardia was significantly higher in patients with a history of myocardial infarction and in men compared with women. There was a progressively increased rate of inducibility with increasing numbers of diseased coronary arteries. There was a significantly lower rate of inducibility in patients with prior coronary artery bypass surgery and in patients who also had noncoronary cardiac disease. The rate of inducibility was higher in patients of white race, patients with recent (

Subject(s)
Cardiac Pacing, Artificial , Coronary Disease/physiopathology , Tachycardia, Ventricular/etiology , Aged , Coronary Disease/complications , Coronary Disease/diagnosis , Electrodiagnosis , Female , Forecasting , Humans , Male , Middle Aged , Myocardial Infarction/complications , Sex Characteristics , Tachycardia, Ventricular/physiopathology
4.
J Am Coll Cardiol ; 31(2): 460-72, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9462593

ABSTRACT

OBJECTIVES: The objective of this study was to determine why sustained ventricular tachycardias (VT) sometimes stop without outside intervention. BACKGROUND: Sustained, monomorphic VT in patients with ischemic heart disease is often caused by reentrant excitation. These tachycardias can degenerate into rapid polymorphic rhythms or occasionally terminate spontaneously. METHODS: Sustained VT was induced by programmed stimulation in dog hearts 4 to 5 days after ligation of the left anterior descending coronary artery. Activation in reentrant circuits in the epicardial border zone of the infarct was mapped using 192 to 312 bipolar electrodes. RESULTS: Spontaneous termination of sustained VT always occurred when the reentrant wave front blocked in the central common pathway in reentrant circuits with a figure-of-eight configuration. Two major patterns of termination were identified from activation maps of the circuits that were not distinguishable from each other on the surface electrocardiogram: 1) Abrupt termination was not preceded by any change in the pattern of activation or cycle length. It could occur at different locations within the central common pathway, was not related to the directions of the muscle fiber orientation and was not caused by a short excitable gap. 2) Termination caused by premature activation (after a short cycle) either resulted from shortening of the functional lines of block around which the reentrant impulse circulated or was caused by wave fronts originating outside the reentrant circuit. In only one episode were oscillations of cycle length associated with termination. CONCLUSIONS: The mechanisms for termination of reentry in functional circuits causing VT are different from those in anatomic circuits where oscillatory behavior precedes termination.


Subject(s)
Body Surface Potential Mapping , Myocardial Infarction/physiopathology , Pericardium/physiopathology , Tachycardia, Atrioventricular Nodal Reentry/physiopathology , Tachycardia, Ventricular/physiopathology , Animals , Atrioventricular Node/physiopathology , Cardiac Pacing, Artificial , Coronary Vessels/surgery , Dogs , Electric Stimulation , Electrocardiography , Heart Block/physiopathology , Heart Rate/physiology , Ligation , Muscle Fibers, Skeletal/pathology , Myocardial Infarction/pathology , Myocardium/pathology , Pericardium/pathology , Remission, Spontaneous , Signal Processing, Computer-Assisted , Tachycardia, Atrioventricular Nodal Reentry/pathology
5.
J Am Coll Cardiol ; 17(1): 1-8, 1991 Jan.
Article in English | MEDLINE | ID: mdl-1702795

ABSTRACT

The Cardiac Arrhythmia Pilot Study (CAPS) was a 1 year trial that analyzed the safety and effectiveness of arrhythmia suppression in 502 patients surviving acute myocardial infarction who had greater than or equal to 10 ventricular premature depolarizations/h or greater than or equal to 5 runs of ventricular tachycardia on a Holter recording obtained 6 to 60 days after the acute infarction. Because 100 of these patients received placebo in a double-blind fashion for 1 year, a comprehensive objective analysis was performed of spontaneous arrhythmia changes based on real data rather than statistical estimates. In the CAPS placebo group, 19% developed some serious clinical event in 1 year (death, heart failure, proarrhythmia) that could likely be attributable to antiarrhythmic drug toxicity. A significant reduction in the frequency of ventricular premature depolarizations (p = 0.004) occurred in the first few weeks of "therapy" with a further significant (p less than 0.04) decrease between 3 to 12 months. After initiation of placebo antiarrhythmic therapy, 27% had "apparent ventricular premature depolarization suppression" (greater than or equal to 70% reduction) after one Holter recording evaluation and nearly half (48%) after six Holter recordings to assess suppression were performed.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Cardiac Complexes, Premature/epidemiology , Myocardial Infarction/complications , Tachycardia/epidemiology , Double-Blind Method , Electrocardiography, Ambulatory , Female , Humans , Male , Middle Aged , Pilot Projects , Placebos , Time Factors
6.
J Am Coll Cardiol ; 24(1): 159-64, 1994 Jul.
Article in English | MEDLINE | ID: mdl-8006260

ABSTRACT

OBJECTIVES: The purpose of this study was to investigate left atrial appendage size, function and thrombus prevalence in patients with atrial "fibrillation-flutter." BACKGROUND: Thrombus formation and peripheral embolization in atrial fibrillation are related to left atrial appendage dysfunction. Embolization occurs less frequently in atrial flutter. It is not known whether the atrial appendage in fibrillation-flutter, which has an intermediate appearance on the surface electrocardiogram (ECG), has distinct characteristics that could affect thrombus formation. METHODS: Sixty-one patients with atrial tachyarrhythmias underwent transesophageal echocardiographic examination of the left atrial appendage. Appendage area, peak emptying velocity and the presence of thrombus and spontaneous echo contrast were determined. The results for 14 patients with fibrillation-flutter (based on ECG fibrillatory wave characteristics) were compared with those for 30 patients with atrial fibrillation and 17 patients with atrial flutter. RESULTS: Both fibrillation-flutter and atrial fibrillation were associated with chaotic appendage flow patterns with similarly low peak emptying velocities (18 +/- 8 and 17 +/- 10 cm/s, mean +/- 1 SD, respectively). Atrial flutter was associated with a regular pattern of appendage contraction and a significantly higher peak emptying velocity (42 +/- 18 cm/s, p < 0.0001). Mean appendage area was similar for fibrillation-flutter and fibrillation (6.3 +/- 2.2 and 6.7 +/- 2.1 cm2, respectively) but was significantly smaller for atrial flutter (5.3 +/- 1.4 cm2, p < 0.05). The prevalence of left atrial appendage thrombus was similar for fibrillation-flutter and atrial fibrillation (40% and 29%, respectively), whereas no patient with atrial flutter had a thrombus (p < 0.05). Similarly, the presence of spontaneous echo contrast was higher for fibrillation-flutter (50%) and atrial fibrillation (40%) than for atrial flutter (6%, p < 0.05). CONCLUSIONS: Left atrial appendage size and function in atrial fibrillation-flutter are indistinguishable from those of typical atrial fibrillation, and the frequency of thrombus and spontaneous echo contrast is similarly high. This is in contrast to atrial flutter, which is characterized by a smaller, more contractile left atrial appendage and a lower frequency of thrombus and spontaneous echo contrast.


Subject(s)
Atrial Fibrillation/diagnostic imaging , Atrial Flutter/diagnostic imaging , Atrial Function, Left , Echocardiography, Transesophageal , Heart Diseases/diagnostic imaging , Thrombosis/diagnostic imaging , Aged , Analysis of Variance , Atrial Fibrillation/complications , Atrial Fibrillation/epidemiology , Atrial Fibrillation/physiopathology , Atrial Flutter/complications , Atrial Flutter/epidemiology , Atrial Flutter/physiopathology , Chi-Square Distribution , Echocardiography, Transesophageal/instrumentation , Echocardiography, Transesophageal/methods , Echocardiography, Transesophageal/statistics & numerical data , Electrocardiography , Female , Heart Diseases/epidemiology , Heart Diseases/etiology , Heart Diseases/physiopathology , Humans , Male , Middle Aged , Prevalence , Thrombosis/epidemiology , Thrombosis/etiology , Thrombosis/physiopathology
7.
Am J Cardiol ; 72(16): 3F-12F, 1993 Nov 26.
Article in English | MEDLINE | ID: mdl-8237828

ABSTRACT

Despite the fact that a number of different electrophysiologic mechanisms are capable of causing cardiac arrhythmias, reentrant excitation has emerged as the most important mechanism causing life-threatening arrhythmias that arise in the ventricles. Pharmacologic therapy of arrhythmias caused by reentry is aimed at preventing the conditions that either facilitate the initiation of the circulating reentrant excitation wave or the conditions that permit its persistence. This involves alterations in either refractoriness or conduction by the drugs. Both atrial and ventricular tachyarrhythmias may follow premature depolarizations that occur at a critical coupling interval to a previous excitation. One desirable property of antiarrhythmic drugs might be to prevent the initiation of reentrant excitation by the triggering premature impulse. Mechanisms are described to show how drugs that prolong the action potential duration (class III antiarrhythmic drugs) might have this effect. It is, however, emphasized that drug effects that have been documented in electrophysiologic studies on normal myocardium might not occur in an arrhythmogenic region that has pathologic alterations, because of changes in the properties of ion channels of the diseased myocardial cells. Antiarrhythmic drugs might also terminate ongoing reentrant excitation by causing block of conduction in the reentrant pathway, at least for one beat. Class III drugs are expected to stop the perpetuation of reentry by prolonging the action potential duration and the refractory period of myocardial fibers in the reentrant circuit to such an extent that the propagating reentrant impulse no longer finds excitable myocardium but blocks in refractory tissue. Therefore, the effectiveness of this drug class to terminate reentry should depend on at least 2 factors: the size of the excitable gap as the reentrant impulse moves around the circuit, which may be related to the mechanism that causes reentry, and the degree to which the drugs can prolong the action potential duration and refractory period at the rapid rates of tachycardia. Each of these factors is discussed with relation to the proposed mechanism of action of drugs that prolong repolarization.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Heart Conduction System/physiopathology , Tachycardia, Atrioventricular Nodal Reentry/drug therapy , Tachycardia, Atrioventricular Nodal Reentry/physiopathology , Tachycardia, Sinoatrial Nodal Reentry/drug therapy , Tachycardia, Sinoatrial Nodal Reentry/physiopathology , Animals , Heart Conduction System/drug effects , Humans
8.
Am J Cardiol ; 81(11): 1373-7, 1998 Jun 01.
Article in English | MEDLINE | ID: mdl-9631982

ABSTRACT

Chronotropic incompetence limits exercise performance in cardiac transplant patients. Electrical linkage of the innervated native sinus node and the denervated donor atrium or direct donor atrium pacing improves exercise performance in patients early after transplant.


Subject(s)
Cardiac Pacing, Artificial , Electrocardiography , Heart Atria/physiopathology , Heart Rate/physiology , Heart Transplantation/physiology , Postoperative Complications/physiopathology , Sinoatrial Node/transplantation , Adult , Aged , Exercise Test , Female , Humans , Male , Middle Aged , Signal Processing, Computer-Assisted , Sinoatrial Node/physiopathology , Treatment Outcome
9.
Am J Cardiol ; 65(9): 539-46, 1990 Mar 01.
Article in English | MEDLINE | ID: mdl-2178379

ABSTRACT

The a priori hypothesis that diltiazem would reduce the frequency and repetitiveness of ventricular arrhythmias was tested 3 months after myocardial infarction in patients participating in the Multicenter Diltiazem Postinfarction Trial. After 3 months of follow-up, 1,546 of the 2,466 patients enrolled had a 24-hour continuous electrocardiographic recording that contained greater than or equal to 12 hours of analyzable data. They were similar to the patients who survived 3 months but chose not to have a 24-hour electrocardiographic recording (i.e., they were representative of the entire group that survived 3 months). After 3 months of follow-up, there were no significant differences between the diltiazem and placebo groups in the prevalence of atrioventricular block, the frequency of atrial arrhythmias or the frequency or repetitiveness of ventricular arrhythmias. Heart rate was significantly lower (67 +/- 12 vs 71 +/- 12 beats/min) and there was a significantly greater proportion of patients with sinus pauses greater than or equal to 2 seconds in duration in the diltiazem group (6%) than in the placebo group (3%). Comparison with placebo revealed no evidence either for an anti- or proarrhythmic effect of diltiazem. There was no reduction in sudden or arrhythmic death attributable to diltiazem treatment; the fraction of total deaths that were arrhythmic by the Hinkle classification was 41% in the placebo group and 42% in the diltiazem group. It may be that the lack of effect of diltiazem on ventricular arrhythmias is partially responsible for its lack of effect on mortality after myocardial infarction.


Subject(s)
Arrhythmias, Cardiac/prevention & control , Diltiazem/therapeutic use , Heart Rate/drug effects , Myocardial Contraction/drug effects , Myocardial Infarction/complications , Adult , Aged , Electrocardiography, Ambulatory , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multicenter Studies as Topic , Randomized Controlled Trials as Topic
10.
Am J Cardiol ; 67(5): 335-42, 1991 Feb 15.
Article in English | MEDLINE | ID: mdl-1994656

ABSTRACT

The effect of diltiazem on long-term outcome after acute myocardial infarction (AMI) was assessed in 2,377 patients enrolled in the Multicenter Diltiazem Post-Infarction Trial and subsequently followed for 25 +/- 8 months. The study population included 855 patients (36%) with at least 1 prior AMI before the index infarction and 1,522 patients (64%) with a first AMI, of whom 409 (27%) had a first non-Q-wave AMI, 664 (44%) a first inferior Q-wave AMI, and 449 (30%) a first anterior Q-wave AMI. This post hoc analysis revealed that, among patients with first non-Q-wave and first inferior Q-wave AMI, there were fewer cardiac events during follow-up in the diltiazem than in the placebo group, and that the reverse was true for patients with first anterior Q-wave AMI or prior infarction. The diltiazem:placebo Cox hazard ratio (95% confidence limits) for the trial primary end point (cardiac death or nonfatal reinfarction, whichever occurred first) was: first non-Q-wave AMI-0.48 (0.26, 0.89); first inferior Q-wave AMI-0.66 (0.40, 1.09); first anterior Q-wave AMI-0.82 (0.51, 1.31); and prior AMI-1.11 (0.85, 1.44). Use of cardiac death alone as an end point gave an even more sharply focused treatment difference: first non-Q-wave AMI-0.46 (0.18, 1.21); first inferior Q-wave AMI-0.53 (0.27, 1.06); first anterior Q-wave AMI-1.28 (0.68, 2.40); prior infarction-1.26 (0.90, 1.77). Further analysis revealed that these differences in the effect of diltiazem in large part reflected the different status of the 4 electrocardiographically defined subsets in terms of left ventricular function.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Diltiazem/therapeutic use , Electrocardiography , Myocardial Infarction/drug therapy , Double-Blind Method , Female , Humans , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Survival Analysis , Ventricular Function, Left/physiology
11.
Am J Cardiol ; 64(1): 11-5, 1989 Jul 01.
Article in English | MEDLINE | ID: mdl-2741803

ABSTRACT

To gain insight into the altered kinetics of creatine kinase-MB (CK-MB) release after reperfusion, a physiologically based model with first-order CK-MB appearance and disappearance functions was postulated. This biexponential model is based on the assumption that reperfusion reestablishes nutritive blood flow, providing direct access of interstitial CK-MB to the bloodstream. This is in contrast to persistent coronary artery occlusion, in which no direct access to nutritive flow is present. The accuracy of this model was examined in 8 dogs reperfused after 2 hours of coronary artery occlusion. The fit to observed values was excellent, with a mean r2 of 0.97 +/- 0.05. In agreement with the biexponential model, the initial increase in CK-MB activity was abrupt and rapid. The same degree of accuracy was found in 21 patients with angiographic evidence of reperfusion after thrombolytic therapy (mean r2 0.97 +/- 0.02). The appearance characteristics were similar to the animal model, with an abrupt and rapid increase in CK-MB activity. When compared with 5 patients with persistent occlusion, ka, the rate constant of the appearance function, clearly distinguished patients with reperfusion (chi-square = 20.6, p less than 0.0001), whereas considerable overlap was present in the time to peak CK-MB (time to peak less than 12 hours, chi-square = 3.6, difference not significant). Alterations of CK-MB release in reperfusion can be accurately modeled with the biexponential model. The characteristics of this model suggest that early identification of reperfusion by serial CK-MB assay is possible.


Subject(s)
Creatine Kinase/metabolism , Myocardial Infarction/therapy , Myocardial Reperfusion , Animals , Dogs , Humans , Isoenzymes , Models, Biological , Myocardial Infarction/enzymology
12.
Psychiatry Res ; 22(4): 341-8, 1987 Dec.
Article in English | MEDLINE | ID: mdl-3432458

ABSTRACT

There are a number of agents claimed effective in provoking panic attacks in the laboratory. For each case, however, the determination of whether an attack has occurred is largely subjective. An objective index of panic would be of great benefit in standardizing laboratory provocation studies. Using heart rate (HR) recordings during sodium lactate infusion, we developed a formula--the heart rate index (HRI)--which appears to correlate well with the subjective experience of panic. Of note is the fact that the HRI was most powerful in identifying attacks that occurred in the first 15 min of the 20-min infusions. In an accompanying study, we examined HR variability during the infusions using the successive difference mean square statistic. HR variability did not change during lactate-induced panic attacks. Therefore, tachycardia during lactate-induced panic probably does not result from decreased vagal tone to the heart.


Subject(s)
Anxiety Disorders/chemically induced , Fear , Heart Rate/drug effects , Lactates , Panic , Adult , Anxiety Disorders/diagnosis , Fear/drug effects , Female , Humans , Lactates/pharmacology , Lactic Acid , Male , Panic/drug effects , Stimulation, Chemical , Time Factors
15.
Cardiovasc Clin ; 22(1): 97-116, 1992.
Article in English | MEDLINE | ID: mdl-1309443

ABSTRACT

Only antiarrhythmic agents with class I activity prolong QRS duration The most marked QRS prolongation is produced by the IC agents, followed by IA and IB. This is consistent with the kinetics of interaction of each of these three subclasses with the sodium channel. Amiodarone's effect on QRS duration is between that of the IB and IA agents consistent with its tau rec of 1.5 seconds. Moricizine's effects on QRS duration are more marked than would be expected from its tau rec of 2.6 seconds but may be explained by the slow onset of inactivation block. The greatest efficacy in VPC suppression is exhibited by the class IC agents and amiodarone. Although amiodarone and sotalol are included in class III, amiodarone has marked class IB activity and sotalol is a more potent beta-adrenergic blocker. The disparate effects of these two drugs in suppressing VPCs may be explained by the class I action of amiodarone. It is surprising that drugs within each subclass correlate at all in VPC suppression in view of the marked heterogeneity of mechanisms potentially producing VPCs. Antiarrhythmic agents with class III activity seem to be the most effective in patients with inducible sustained ventricular tachyarrhythmias. Except for the class I agents with class III activity, that is, IA agents, all class I agents are effective in only 10% to 15% of patients with inducible ventricular tachycardia. The discordance between sotalol and amiodarone is unexplained. As expected, the most marked prolongation of ventricular tachycardia cycle length occurs with the class IC agents, followed by class IA and IB. At the rapid rates of the ventricular tachycardia, frequency-dependent sodium channel block occurs even with the "fast IB" drugs, and ventricular tachycardia cycle length is prolonged.


Subject(s)
Anti-Arrhythmia Agents/classification , Electrophysiology , Sodium Channels/drug effects , Action Potentials/drug effects , Anti-Arrhythmia Agents/pharmacology , Anti-Arrhythmia Agents/therapeutic use , Humans , Models, Molecular , Receptors, Drug/drug effects , Time Factors
16.
Circulation ; 96(9): 3136-47, 1997 Nov 04.
Article in English | MEDLINE | ID: mdl-9386186

ABSTRACT

BACKGROUND: During initiation of tachycardias by programmed stimulation (PES), an inverse relationship between the coupling interval of the premature impulse (V1V2) and the interval between the premature impulse and the first impulse of tachycardia (V2T1) has been proposed to be a specific indicator of reentry. However, an inverse relationship has not always been observed during initiation of clinical reentrant ventricular tachycardias (VTs). METHODS AND RESULTS: Reentrant VT was initiated by PES in twelve 4-day-old infarcted dog hearts. The relationship between V1V2 and V2T1 was always direct. Mapping of the epicardial border zone (EBZ) indicated that initiation of VT was secondary to functional orthodromic block of V2, propagation of V2 around the line of block, and antidromic propagation through the original location of the block. In 7 dogs, the line of orthodromic block and the pathway of orthodromic propagation were similar for different V1V2 coupling intervals. Orthodromic conduction time around the line to its distal side was longer at shorter V1V2 intervals, but a shorter antidromic delay in the area of unidirectional block for shorter V1V2 intervals, possibly reflecting small changes in the conduction pathway involving deeper layers of the EBZ, resulted in shorter V2T1 intervals. In the other 5 dogs, the orthodromic conduction pathway of V2 around the line of block changed markedly, with a shorter pathway for shorter V1V2 intervals resulting in shorter V2T1 intervals. CONCLUSIONS: An inverse relationship between V1V2 and V2T1 is not a specific indicator of functional reentry.


Subject(s)
Tachycardia, Ventricular/etiology , Animals , Dogs , Electrocardiography , Heart Conduction System/physiology
17.
Circulation ; 87(4): 1286-305, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8462153

ABSTRACT

BACKGROUND: Clinical electrophysiology studies have used, for the most part, models of anatomic reentrant circuits to explain entrainment of ventricular tachycardia. Our studies use activation maps to directly determine mechanisms of entrainment of functional circuits that cause tachycardia. METHODS AND RESULTS: Electrograms were recorded from 192 sites on reentrant circuits in the epicardial border zone of canine myocardial infarcts during sustained ventricular tachycardia. Overdrive stimulation from different sites and at different cycle lengths was investigated. The reentrant circuits were shown to be functional, yet stimulated impulses could enter and repetitively reset the circuits (entrainment), demonstrating the presence of an excitable gap. Entrainment could occur from different stimulation sites with the stimulated impulses from each site activating the circuit with a different pattern. Entrainment, however, did not occur when the stimulated wave fronts obliterated the lines of functional block in the circuit. Fusion on the ECG occurred during entrainment when the stimulated impulses activated the ventricles concurrently with a previous stimulated impulse leaving the reentrant circuit at a different site. The first postpacing QRS was captured but not fused because it was caused by the last stimulated impulse emerging from the circuit. The first postpacing cycle length on the ECG was either equal to or longer than the overdrive cycle length depending on whether there was a fusion QRS during overdrive. The first postpacing cycle length at sites in the reentrant circuit equaled the pacing cycle length. At an appropriately short overdrive cycle length, stimulated impulses blocked in the circuit to terminate reentry. CONCLUSIONS: Functional reentrant circuits causing ventricular tachycardia can be reset and entrained. Activation maps directly show the mechanisms.


Subject(s)
Cardiac Pacing, Artificial/methods , Heart Conduction System/physiopathology , Myocardial Infarction/physiopathology , Tachycardia, Ventricular/physiopathology , Animals , Dogs , Electrocardiography , Electrophysiology , Myocardial Infarction/complications , Signal Processing, Computer-Assisted , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/etiology
18.
Anesth Analg ; 76(4): 705-13, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8466005

ABSTRACT

We evaluated the impact of prophylactic nitroglycerin on the incidence of perioperative myocardial ischemia in patients with known or suspected coronary artery disease who undergo noncardiac surgery. Our goals were to better define the role of nitroglycerin in the management of high-risk patients and to explore the mechanisms of perioperative myocardial ischemia. Patients were assigned randomly to either a control group (n = 23) or to receive 0.9 micrograms.kg-1.min-1 of intravenous nitroglycerin (n = 22). The diagnosis of myocardial ischemia was based on a review of Holter electrocardiogram (ECG) recordings. There was no difference in the incidence of ischemia between groups. Seven control patients (30%) and seven nitroglycerin patients (32%) exhibited ECG evidence of ischemia. The preponderance of myocardial ischemia occurred during emergence from anesthesia (of the 14 patients exhibiting ischemia, 12 did so at emergence). There was an acute increase in heart rate at the onset of ischemia in all patients exhibiting ischemia with 14 of 18 episodes associated with an increase of 20% or greater. The heart rate associated with the onset of ischemia was greater in the nitroglycerin-treated patients than in the control group. We also found that the occurrence of myocardial ischemia on a preoperative Holter recording was strongly predictive of the subsequent occurrence of perioperative ischemia. In conclusion, the addition of nitroglycerin to standard anesthetic management of these high-risk patients does not measurably reduce perioperative ischemia.


Subject(s)
Intraoperative Complications/prevention & control , Myocardial Ischemia/prevention & control , Nitroglycerin/therapeutic use , Aged , Blood Pressure/physiology , Coronary Disease/complications , Coronary Disease/physiopathology , Double-Blind Method , Electrocardiography, Ambulatory , Female , Heart Rate/physiology , Humans , Infusions, Intravenous , Male , Middle Aged , Myocardial Ischemia/etiology , Myocardial Ischemia/physiopathology , Prognosis , Systole/physiology
19.
Circulation ; 91(8): 2245-63, 1995 Apr 15.
Article in English | MEDLINE | ID: mdl-7697855

ABSTRACT

BACKGROUND: The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect). Since some ventricular tachycardias may be caused by anisotropic reentry, we determined the effects of flecainide on this mechanism for reentry in infarcted canine hearts in order to determine possible causes for its clinical effects. METHODS AND RESULTS: The effects of flecainide were determined on ventricular tachycardia induced by programmed electrical stimulation in dogs with healing myocardial infarction 4 days after coronary artery occlusion. Activation in the reentrant circuits causing tachycardia was mapped with a 196-channel computerized mapping system. We found that flecainide converted inducible unsustained ventricular tachycardia to inducible sustained ventricular tachycardia by modifying conduction in the reentrant circuit. In general, by slowing conduction, the reentrant wave front did not block after flecainide, leading to perpetuation of reentrant excitation. When sustained ventricular tachycardia could be induced before the drug, flecainide prolonged the coupling interval of premature impulses necessary to induce tachycardia by lengthening the line of block and slowing conduction around it. Flecainide also slowed the rate of the tachycardia but did not terminate it. The anisotropic reentrant circuits were modified so that the central common pathway of "figure-of-eight" circuits was narrowed and lengthened due to extension of the lines of block that bounded the pathways. Extension of the lines of block resulted from depression of conduction in the direction transverse to the long axis of the myocardial fiber bundles caused by flecainide. Flecainide also slowed conduction in the longitudinal direction in part of the circuits. The depressant effects of flecainide on both longitudinal and transverse anisotropic conduction were quantified by pacing from the center of the electrode array and it was found, contrary to predictions, that transverse conduction was depressed as much as longitudinal conduction. CONCLUSIONS: Flecainide slows conduction in both the longitudinal and transverse direction relative to the orientation of the myocardial fibers. This enables sustained reentry to occur more easily. Flecainide does not cause conduction block in crucial regions of reentrant circuits (central common pathway) and therefore does not prevent reentrant tachycardia in healing infarcts.


Subject(s)
Flecainide/pharmacology , Heart Conduction System/drug effects , Myocardial Infarction/physiopathology , Tachycardia, Ventricular/physiopathology , Animals , Anisotropy , Arrhythmias, Cardiac/chemically induced , Cardiac Pacing, Artificial , Dogs , Electrocardiography , Electrophysiology , Flecainide/adverse effects , Flecainide/therapeutic use , Heart Conduction System/physiopathology
20.
Circulation ; 98(23): 2598-607, 1998 Dec 08.
Article in English | MEDLINE | ID: mdl-9843469

ABSTRACT

BACKGROUND: The complete reentrant circuit for ablation of reentrant ventricular tachycardia (VT) in humans can rarely be localized by mapping. As a result, surrogate markers, such as diastolic electrical activity, subsequently confirmed by entrainment, have been used. However, ablation at those sites has had variable efficacy. The reasons for this variability are not clear. METHODS AND RESULTS: We correlated activation maps of reentrant circuits in the epicardial border zone of 4-day old infarcted dog hearts with the corresponding ECGs for 45 VTs to determine the regions of the reentrant circuits activated during diastole. In VTs with a figure-8 reentrant pattern, the center point of the central common pathway, the part of the circuit critical for the maintenance of reentry, was activated in early diastole in 32 of 35 VTs (91.4%), in late diastole in 1 (2.9%), and in systole in 2 (5.7%). Regions outside the circuit were rarely activated in diastole. In 10 VTs, the reentrant circuit was characterized by a single reentrant loop. In these circuits, no one region was predicted to be critical for maintenance of reentry, and a segment of the circuits was activated during diastole. However, regions peripheral to the circuit were also activated during diastole. CONCLUSIONS: The pattern of reentrant activation determines the specificity of diastolic activity for locating critical sites for ablation of VT.


Subject(s)
Electrophysiology , Myocardial Infarction/physiopathology , Tachycardia, Ventricular/physiopathology , Animals , Diastole , Dogs
SELECTION OF CITATIONS
SEARCH DETAIL